Cardiac function in an african dialysis population with a low prevalence of pre-existing cardiovascular disease

Renal Failure

Volumn 31, Issue 3, 2009, Pages 211-220

  Luyckx, Valerie A ^a   Yip, Anthony ^b   Sofianou, Lana ^b   Jhangri, Gian S ^a   Mueller, Thomas F ^a   Naicker, Saraladevi ^c  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^c UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

Black African; Cardiovascular outcomes; Dialysis; Ejection fraction; Left ventricular hypertrophy; Systolic function

Indexed keywords

ADULT; AFRICA; ARTICLE; CARDIOVASCULAR DISEASE; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAM; FEMALE; FOLLOW UP; HEART FAILURE; HEART FUNCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE HYPERTROPHY; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; INCIDENCE; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MORTALITY; OUTCOME ASSESSMENT; PERITONEAL DIALYSIS; PREVALENCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SURVIVOR; SYSTOLIC DYSFUNCTION; TREATMENT DURATION; CAUSE OF DEATH; CHRONIC KIDNEY FAILURE; COMORBIDITY; ETHNOLOGY; HEART FUNCTION TEST; HEART STROKE VOLUME; MIDDLE AGED; NEGRO; PATHOPHYSIOLOGY; RENAL REPLACEMENT THERAPY; SOUTH AFRICA;

ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; COMORBIDITY; ECHOCARDIOGRAPHY; FEMALE; HEART FUNCTION TESTS; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PERITONEAL DIALYSIS; PREVALENCE; RENAL DIALYSIS; SOUTH AFRICA; STROKE VOLUME;

EID: 65549083008     PISSN: 0886022X     EISSN: 15256049     Source Type: Journal    
DOI: 10.1080/08860220802669867     Document Type: Article

References (60)

1. Foley RN, Parfrey PS, Harnett JD, et al. Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney Int. 1995 Jan;47(1):186-192.
2. Foley RN, Parfrey PS, Kent GM, Harnett JD, Murray DC, Barre PE. Long-term evolution of cardiomyopathy in dialysis patients. Kidney Int. 1998 Nov;54(5):1720-1725.
3. Parfrey PS, Foley RN. The clinical epidemiology of cardiac disease in chronic renal failure. J Am Soc Nephrol. 1999 Jul;10(7):1606-1615.
4. Silberberg JS, Barre PE, Prichard SS, Sniderman AD. Impact of left ventricular hypertrophy on survival in end-stage renal disease. Kidney Int. 1989 Aug;36(2):286-290.
5. Collins AJ, Li S, Ma JZ, Herzog C. Cardiovascular disease in end-stage renal disease patients. Am J Kidney Dis. 2001 Oct; 38(4 Suppl. 1):S26-S29.
6. Harnett JD, Foley RN, Kent GM, Barre PE, Murray D, Parfrey PS. Congestive heart failure in dialysis patients: Prevalence, incidence, prognosis and risk factors. Kidney Int. 1995 Mar;47(3):884-890.
7. Ritz E, Wanner C. The challenge of sudden death in dialysis patients. Clin J Am Soc Nephrol. 2008 May;3(3):920-929.
8. Locatelli F, Covic A, Chazot C, Leunissen K, Luno J, Yaqoob M. Hypertension and cardiovascular risk assessment in dialysis patients. Nephrol Dial Transplant. 2004 May; 19(5):1058-1068.
9. Hase H, Joki N, Ishikawa H, et al. Independent risk factors for progression of coronary atherosclerosis in hemodialysis patients. Ther Apher Dial. 2006 Aug;10(4):321-327.
10. Hase H, Tsunoda T, Tanaka Y, et al. Risk factors for de novo acute cardiac events in patients initiating hemodialysis with no previous cardiac symptom. Kidney Int. 2006 Sep; 70(6):1142-1148.
11. Kessler M, Zannad F, Lehert P, et al. Predictors of cardiovascular events in patients with end-stage renal disease: An analysis from the Fosinopril in dialysis study. Nephrol Dial Transplant. 2007 Dec;22(12):3573-3579.
12. Longenecker JC, Coresh J, Powe NR, et al. Traditional cardiovascular disease risk factors in dialysis patients compared with the general population: The CHOICE Study. J Am Soc Nephrol. 2002 Jul;13(7):1918-1927.
13. Nishimura M, Tsukamoto K, Hasebe N, Tamaki N, Kikuchi K, Ono T. Prediction of cardiac death in hemodialysis patients by myocardial fatty acid imaging. J Am Coll Cardiol. 2008 Jan 15;51(2):139-145.
14. Owen WF, Madore F, Brenner BM. An observational study of cardiovascular characteristics of long-term end-stage renal disease survivors. Am J Kidney Dis. 1996 Dec;28(6): 931-936.
15. McCullough PA, Jurkovitz CT, Pergola PE, et al. Independent components of chronic kidney disease as a cardiovascular risk state: Results from the Kidney Early Evaluation Program (KEEP). Arch Intern Med. 2007 Jun 11; 167(11):1122-1129.
16. Parfrey PS, Foley RN, Harnett JD, Kent GM, Murray DC, Barre PE. Outcome and risk factors for left ventricular disorders in chronic uraemia. Nephrol Dial Transplant. 1996 Jul;11(7):1277-1285.
17. Foley RN, Parfrey PS, Kent GM, Harnett JD, Murray DC, Barre PE. Serial change in echocardiographic parameters and cardiac failure in end-stage renal disease. J Am Soc Nephrol. 2000 May;11(5):912-916.
18. Locatelli F, Marcelli D, Conte F, et al. Survival and development of cardiovascular disease by modality of treatment in patients with end-stage renal disease. J Am Soc Nephrol. 2001 Nov;12(11):2411-2417.
19. Barnes E, Dutka DP, Khan M, Camici PG, Hall RJ. Effect of repeated episodes of reversible myocardial ischemia on myo-cardial blood flow and function in humans. Am J Physiol Heart Circ Physiol. 2002 May;282(5):H1603-H1608.
20. Bos WJ, Bruin S, van Olden RW, et al. Cardiac and hemody-namic effects of hemodialysis and ultrafiltration. Am J Kidney Dis. 2000 May;35(5):819-826.
21. Covic A, Goldsmith DJ, Panaghiu L, Covic M, Sedor J. Analysis of the effect of hemodialysis on peripheral and central arterial pressure waveforms. Kidney Int. 2000 Jun; 57(6):2634-2643.
22. McIntyre CW, Burton JO, Selby NM, et al. Hemodialysis-induced cardiac dysfunction is associated with an acute reduction in global and segmental myocardial blood flow. Clin J Am Soc Nephrol. 2008 Jan;3(1):19-26.
23. Selby NM, Fonseca S, Hulme L, Fluck RJ, Taal MW, McIntyre CW. Automated peritoneal dialysis has significant effects on systemic hemodynamics. Perit Dial Int. 2006 May-Jun;26(3):328-335.
24. Selby NM, McIntyre CW. The acute cardiac effects of dialysis. Semin Dial. 2007 May-Jun;20(3):220-228.
25. Verbeke F, Van Biesen W, Pletinck A, Van Bortel LM, Vanholder R. Acute central hemodynamic effects of a volume exchange in peritoneal dialysis. Perit Dial Int. 2008 Mar-Apr;28(2):142-148.
26. Cooper HA, Braunwald E. Clinical importance of stunned and hibernating myocardium. Coron Artery Dis. 2001 Aug;12(5):387-392.
27. Vonesh EF, Moran J. Mortality in end-stage renal disease: A reassessment of differences between patients treated with hemodialysis and peritoneal dialysis. J Am Soc Nephrol. 1999 Feb;10(2):354-365.
28. Ganesh SK, Hulbert-Shearon T, Port FK, Eagle K, Stack AG. Mortality differences by dialysis modality among incident ESRD patients with and without coronary artery disease. J Am Soc Nephrol. 2003 Feb;14(2):415-424.
29. Stack AG, Molony DA, Rahman NS, Dosekun A, Murthy B. Impact of dialysis modality on survival of new ESRD patients with congestive heart failure in the United States. Kidney Int. 2003 Sep;64(3):1071-1079.
30. Kronenberg F, Lingenhel A, Neyer U, et al. Prevalence of dyslipidemic risk factors in hemodialysis and CAPD patients. Kidney Int Suppl. 2003 May(84):S113-S116.
31. Sliwa K, Wilkinson D, Hansen C, et al. Spectrum of heart disease and risk factors in a black urban population in South Africa (the Heart of Soweto Study): A cohort study. Lancet. 2008 Mar 15;371(9616):915-922.
32. Katz I. Kidney and kidney related chronic diseases in South Africa and chronic disease intervention program experiences. Adv Chronic Kidney Dis. 2005 Jan;12(1):14-21.
33. Naicker S. End-stage renal disease in sub-Saharan and South Africa. Kidney Int Suppl. 2003 Feb(83):S119-S122.
34. Parfrey PS, Foley RN, Harnett JD, Kent GM, Murray D, Barre PE. Outcome and risk factors of ischemic heart disease in chronic uremia. Kidney Int. 1996 May;49(5):1428-1434.
35. London GM, Pannier B, Guerin AP, et al. Alterations of left ventricular hypertrophy in and survival of patients receiving hemodialysis: Follow-up of an interventional study. J Am Soc Nephrol. 2001 Dec;12(12):2759-2767.
36. Zoccali C, Benedetto FA, Mallamaci F, et al. Prognostic value of echocardiographic indicators of left ventricular systolic function in asymptomatic dialysis patients. J Am Soc Nephrol. 2004 Apr;15(4):1029-1037.
37. Takeda K, Nakamoto M, Baba M, et al. Echocardiographic evaluation in long-term continuous ambulatory peritoneal dialysis compared with the hemodialysis patients. Clin Nephrol. 1998 May;49(5):308-312.
38. Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE. The prognostic importance of left ventricular geometry in uremic cardiomyopathy. J Am Soc Nephrol. 1995 Jun;5(12):2024-2031.
39. Fathi R, Isbel N, Haluska B, Case C, Johnson DW, Marwick TH. Correlates of subclinical left ventricular dysfunction in ESRD. Am J Kidney Dis. 2003 May;41(5):1016-1025.
40. de Simone G. Left ventricular geometry and hypotension in end-stage renal disease: A mechanical perspective. J Am Soc Nephrol. 2003 Oct;14(10):2421-2427.
41. Middleton RJ, Parfrey PS, Foley RN. Left ventricular hypertrophy in the renal patient. J Am Soc Nephrol. 2001 May; 12(5):1079-1084.
42. Lepira FB, Kayembe PK, M'Buyamba-Kabangu JR, Nseka MN. Clinical correlates of left ventricular hypertrophy in black patients with arterial hypertension. Cardiovasc J S Afr. 2006 Jan-Feb;17(1):7-11.
43. Skudicky D, Sareli P, Libhaber E, et al. Relationship between treatment-induced changes in left ventricular mass and blood pressure in black African hypertensive patients: Results of the Baragwanath Trial. Circulation. 2002 Feb 19;105(7):830-836.
44. De Lima JJ, Sesso R, Abensur H, et al. Predictors of mortality in long-term haemodialysis patients with a low prevalence of comorbid conditions. Nephrol Dial Transplant. 1995;10(9):1708-1713.
45. Covic A, Mardare NG, Ardeleanu S, Prisada O, Gusbeth-Tatomir P, Goldsmith DJ. Serial echocardiographic changes in patients on hemodialysis: an evaluation of guideline implementation. J Nephrol. 2006 Nov-Dec;19(6):783-793.
46. Ganesh SK, Stack AG, Levin NW, Hulbert-Shearon T, Port FK. Association of elevated serum PO(4), Ca × PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol. 2001 Oct;12(10):2131-2138.
47. Moon KH, Song IS, Yang WS, et al. Hypoalbuminemia as a risk factor for progressive left-ventricular hypertrophy in hemodialysis patients. Am J Nephrol. 2000 Sep-Oct;20(5): 396-401.
48. Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE. The impact of anemia on cardiomyopathy, morbidity, and mortality in end-stage renal disease. Am J Kidney Dis. 1996 Jul;28(1):53-61.
49. Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE. Impact of hypertension on cardiomyopathy, morbidity and mortality in end-stage renal disease. Kidney Int. 1996 May;49(5):1379-1385.
50. Kalantar-Zadeh K, Block G, Humphreys MH, Kopple JD. Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients. Kidney Int. 2003 Mar;63(3): 793-808.
51. Bouchard J, Madore F. Inadequate treatment of congestive heart failure in dialysis patients. Semin Dial. 2007 Sep-Oct; 20(5):383-386.
52. Gowdak LH, Arantes RL, de Paula FJ, Krieger EM, De Lima JJ. Underuse of American College of Cardiology/American Heart Association Guidelines in hemodialysis patients. Ren Fail. 2007;29(5):559-565.
53. Roy P, Bouchard J, Amyot R, Madore F. Prescription patterns of pharmacological agents for left ventricular systolic dysfunction among hemodialysis patients. Am J Kidney Dis. 2006 Oct;48(4):645-651.
54. Cice G, Ferrara L, D'Andrea A, et al. Carvedilol increases two-year survival in dialysis patients with dilated cardiomy-opathy: A prospective, placebo-controlled trial. J Am Coll Cardiol. 2003 May 7;41(9):1438-1444.
55. Zannad F, Kessler M, Lehert P, et al. Prevention of cardiovascular events in end-stage renal disease: Results of a randomized trial of fosinopril and implications for future studies. Kidney Int. 2006 Oct;70(7):1318-1324.
56. Chung A, Iheonunekwu N, Gilbert DT, Barton EN. Cardiac disease in dialysis patients in a Jamaican hospital: Echocar-diographic findings that predict mortality. West Indian Med J. 2007 Jun;56(3):305-308.
57. Mehrotra R, Kermah D, Fried L, Adler S, Norris K. Racial differences in mortality among those with CKD. J Am Soc Nephrol. 2008 Jul;19(7):1403-1410. E-pub 2008 Apr 2.
58. Volkova N, McClellan W, Soucie JM, Schoolwerth A. Racial disparities in the prevalence of cardiovascular disease among incident end-stage renal disease patients. Nephrol Dial Transplant. 2006 Aug;21(8):2202-2209.
59. Young BA, Rudser K, Kestenbaum B, Seliger SL, Andress D, Boyko EJ. Racial and ethnic differences in incident myocar-dial infarction in end-stage renal disease patients: The USRDS. Kidney Int. 2006 May;69(9):1691-1698.
60. Liggett SB, Cresci S, Kelly RJ, et al. A GRK5 polymorphism that inhibits beta-adrenergic receptor signaling is protective in heart failure. Nat Med. 2008 May;14(5):510-517.